At present, Bristol-Myers Squibb, Merck and Pfizer outsource 40% of their API demand to CMO/CDMO enterprises. Large-scale layoffs and accelerated plant closures of more pharmaceutical enterprises mean that CMO/CDMO enterprises win more business opportunities in the industry.
 
China has sound laws and regulations on IPR protection, including patent and trademark laws, and has signed 17 international multilateral treaties on IPR protection, including the WIPO Convention, the Paris Convention and the Berne Convention. Among emerging markets with the same low labor costs, the Chinese market enjoys a comparative advantage.
     
Beltroad sustained and in-depth cooperation with the world's leading scientists, in addition to the conventional CMO production services, continuously upgrade CDMO research and development capabilities, to provide drug firms applied technology research and development and industrialization of high technology added value, including the innovation medicine production process development and optimization, formulation development and trial production services, maintain the leading advantages of chiral synthesis, fluorine chemistry, continuous reaction，biological catalysis and other technological areas.